NL-OMON48654
Completed
Not Applicable
Biomarkers and cardiovascular risk in disease models of non-alcoholic fatty liver disease - Cardiovascular risk in NAFLD
Medisch Universitair Ziekenhuis Maastricht0 sites85 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Medisch Universitair Ziekenhuis Maastricht
- Enrollment
- 85
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy individuals:
- •\- age \>\<\= 18 years, NAFLD disease models (n\<\=15 per group):
- •\- diagnosis of glycogen storage disease 1a (GSD1a), familial partial
- •lipodystrophy (FPL), maturity\-onset diabetes of the young type 2 (MODY2\) or
- •abetalipoproteniemia/familial hypobetalipoproteinemia
- •\- age \>\<\= 18 years
Exclusion Criteria
- •\- Contraindications for MRI (i.e. claustrophobia, heart pacemaker or other
- •electronic devices implanted in the body, history of collapse or seizure, or
- •pregnancies \< 12 weeks)
- •\- Inability to give inform consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Biomarkers for cardiovascular disease in chronic kidney diseasechronic kidney diseaseJPRN-UMIN000029758Division of nephrology, Kobe university graduate school of medicine1,050
Completed
Not Applicable
Identification of cardiovascular risk factors in childrePediatric obesityheart rateC18.654.726.500.720E01.370.600.875.500RBR-6bcj43niversidade do Oeste Paulista
Not yet recruiting
Not Applicable
Applying Novel Biomarkers to Assess Cardiac Risk in Patients Undergoing Major Vascular Surgery: Defining Iron, Oxidative Stress, Inflammation, Matrix Metalloproteinases, Coagulation Factors, Lipidomics, Endothelial Dysfunction and Other Relevant Markers as Novel Risk PredictorsACTRN12608000437369The Alfred Hospital200
Completed
Not Applicable
Do women with polycystic ovary syndrome have increased cardiovascular risk compared to normal controls and could this risk be reduced by liraglutide?ISRCTN48560305Hull and East Yorkshire Hospitals NHS Trust (UK)40
Active, not recruiting
Not Applicable
Are early and late cardiovascular risk markers in women with Polycystic Ovary Syndrome increased with concomitant Nonalcoholic Steatohepatitis and can this be modified with Exenatide? - CV risk in PCOS and NASHEUCTR2008-006928-55-GBHull and East Yorkshire NHS Trust